Published in BMC Infect Dis on March 28, 2014
Theory and strategy for Pneumococcal vaccines in the elderly. Hum Vaccin Immunother (2016) 0.80
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 11.94
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med (2003) 7.39
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1997) 7.36
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med (1991) 6.07
Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA (2001) 4.90
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med (1995) 4.38
PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES. J Exp Med (1945) 3.91
Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2008) 3.13
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J (2002) 2.94
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine (2003) 2.87
Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med (2003) 2.87
Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine (2012) 2.43
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA (2012) 2.42
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J (2006) 2.10
23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec (2008) 1.92
Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 1.76
Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med (2007) 1.76
The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis (2005) 1.64
Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet (1977) 1.58
Clinical and economic burden of pneumococcal disease in older US adults. Vaccine (2010) 1.55
Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) (2000) 1.50
Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis (2000) 1.29
Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med (1999) 1.26
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
[Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions]. Rev Epidemiol Sante Publique (1985) 1.19
Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax (2005) 1.17
Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine (2009) 1.14
Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine (2008) 1.14
Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine (2004) 1.14
Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest (1987) 1.13
Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ (1987) 1.12
Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study. Arch Intern Med (Chic) (1947) 1.10
Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine (2002) 1.09
Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis (2007) 1.05
Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med (1999) 1.04
Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics (2009) 1.04
Role of the immune system in aging and longevity. Curr Aging Sci (2011) 0.98
Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric radiologically confirmed community acquired pneumonia following PCV7 introduction in Switzerland. BMC Infect Dis (2013) 0.93
Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol (1986) 0.90
Clinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dôme, France, 1994-1998. Eur J Clin Microbiol Infect Dis (2001) 0.90
Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine (2009) 0.87
Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Vaccine (2011) 0.82
[Economic cost of Streptococcus pneumoniae community-acquired pneumonia, meningitis and bacteremia in an adult population that required hospitalization in Bogotá, Colombia]. Biomedica (2014) 0.77
[The impact of pneumococcal disease on adults living in Bogota, Colombia, 2008]. Rev Salud Publica (Bogota) (2010) 0.76